Territory R/F/TAF Product Sample Clauses

Territory R/F/TAF Product. During the Term, subject to the terms and conditions of this Agreement and any Ancillary Agreements, Xxxxxxx shall have the non-exclusive right to Detail, at its expense, the Territory R/F/TAF Product in each country listed in Annex FF. Subject to the preceding sentence, Detailing by Xxxxxxx or its applicable Affiliate under this Section 6.3.1.2 may commence upon or after the First Commercial Sale of the Territory R/F/TAF Product in the applicable country; provided, however, that if Xxxxxxx or its applicable Affiliate decides not to commence Detailing the Territory R/F/TAF Product in a country upon the First Commercial Sale of the Territory R/F/TAF Product in such country, or to commence Detailing the Territory R/F/TAF Product in a country at any time after the First Commercial Sale of the Territory R/F/TAF Product in such country, Xxxxxxx shall notify Gilead of such decision promptly after such decision is made.
AutoNDA by SimpleDocs
Territory R/F/TAF Product. Before the First Commercial Sale of the Territory R/F/TAF Product in a Major Market Country, Gilead shall develop and propose to Xxxxxxx a set of core messages with respect to the Territory R/F/TAF Product, which core messages shall serve as a basis for the promotion of the Territory R/F/TAF Product in such countries to physicians (as updated from time to time, the “R/F/TAF Product Key Selling Messages” and, together with the Complera Key Selling Messages, the “Key Selling Messages”). From time to time, Gilead may develop and propose to Xxxxxxx updates to the R/F/TAF Product Key Selling Messages. All R/F/TAF Product Key Selling Messages, including updates thereto, shall be consistent with the Product Label for the Territory R/F/TAF Product and scientifically accurate. At Xxxxxxx’x request, the Parties shall discuss such proposed or updated R/F/TAF Product Key Selling Messages and Gilead shall consider Xxxxxxx’x comments. If the Parties cannot reach agreement with respect to any such R/F/TAF Product Key Selling Message or any updates thereto, the Parties may refer any disputed issues to the Executives for resolution pursuant to Section 20.6. If the Executives are unable to reach agreement with respect thereto within the Executives Review Period, Gilead shall have final decision-making authority with respect to such matter.
Territory R/F/TAF Product. In the R/F/TAF Launch Period, Gilead shall perform [*] Details of the Territory R/F/TAF Product in [*].

Related to Territory R/F/TAF Product

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Manufacture of Product Prior to commercialization of the Product, the Parties may, if appropriate for both parties, negotiate in good faith a manufacturing and supply agreement to provide for Licensor to fulfill the manufacturing requirements of Licensee for Product for sale in the European market. The cost of such manufacturing shall not be greater than * percent (*%) of the cost of any competitor cGMP contract manufacturing facility that proposes to manufacturer the Product for Licensee. * Confidential information has been omitted and filed confidentially with the Securities and Exchange Commission.

  • Territory The territorial limits of this Agreement shall be identical with those of the Reinsured Contracts.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Combination Product The term “

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.